Replicor Inc.
Replicor is a clinical-stage biopharmaceutical company dedicated to developing a cure for hepatitis B (HBV) and hepatitis delta (HDV) infections. They focus on nucleic acid polymers (NAPs), especially their lead candidate REP 2139, which has shown remarkable safety, tolerability, and potent antiviral effects in clinical trials. Their mission is to achieve functional cure of HBV and HDV through innovative combination therapies, targeting the clearance of HBsAg and inactivation of cccDNA, ultimately reducing the burden of chronic hepatitis B and D worldwide.
Industries
Nr. of Employees
medium (51-250)
Replicor Inc.
6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada
Patents
Products
Lead sequence-independent oligonucleotide clinical candidate (optimized phosphorothioate oligonucleotide, subcutaneous formulation)
An optimized sequence-independent phosphorothioate oligonucleotide engineered with ribose and nucleotide modifications and formulated as a magnesium salt for once-weekly subcutaneous administration; developed to reduce circulating viral surface antigen and inhibit viral replication and particle secretion.
Sequence-independent oligonucleotide polymer therapeutic platform
A platform approach leveraging sequence-independent oligonucleotide polymers that interact with exposed hydrophobic protein interfaces to inhibit assembly and secretion of viral subviral particles and produce broad-spectrum antiviral effects.
Lead sequence-independent oligonucleotide clinical candidate (optimized phosphorothioate oligonucleotide, subcutaneous formulation)
An optimized sequence-independent phosphorothioate oligonucleotide engineered with ribose and nucleotide modifications and formulated as a magnesium salt for once-weekly subcutaneous administration; developed to reduce circulating viral surface antigen and inhibit viral replication and particle secretion.
Sequence-independent oligonucleotide polymer therapeutic platform
A platform approach leveraging sequence-independent oligonucleotide polymers that interact with exposed hydrophobic protein interfaces to inhibit assembly and secretion of viral subviral particles and produce broad-spectrum antiviral effects.
Services
Provision of expanded access to an investigational once-weekly subcutaneous sequence-independent oligonucleotide therapeutic for patients with advanced viral hepatitis; includes case review, investigator qualification, site participation, clinical oversight and collection of bridging safety and efficacy data. Program has been used in patients with advanced cirrhosis and in patients with HBV/HDV/HIV co-infection.
Design and implementation of multi-center proof-of-concept and Phase II clinical studies, including protocol development, endpoint selection, biomarker integration and data analysis focused on antigen reduction and functional cure outcomes.
Partner-based laboratory studies with academic and government institutions to identify mechanisms of action, perform antiviral testing, and validate targets using molecular biology, biochemistry and in vivo models.
Provision of expanded access to an investigational once-weekly subcutaneous sequence-independent oligonucleotide therapeutic for patients with advanced viral hepatitis; includes case review, investigator qualification, site participation, clinical oversight and collection of bridging safety and efficacy data. Program has been used in patients with advanced cirrhosis and in patients with HBV/HDV/HIV co-infection.
Design and implementation of multi-center proof-of-concept and Phase II clinical studies, including protocol development, endpoint selection, biomarker integration and data analysis focused on antigen reduction and functional cure outcomes.
Partner-based laboratory studies with academic and government institutions to identify mechanisms of action, perform antiviral testing, and validate targets using molecular biology, biochemistry and in vivo models.
Expertise Areas
- Sequence-independent oligonucleotide therapeutics development
- Preclinical infectious disease modeling (hepatocyte models, avian and rodent hepadnavirus models)
- Clinical trial design and execution for viral hepatitis
- Antiviral mechanism identification and biochemical target elucidation
Key Technologies
- Phosphorothioate-modified oligonucleotides
- Sequence-independent oligonucleotide polymer platform
- Subcutaneous salt formulations (magnesium salt) for oligonucleotides
- In vitro hepatocyte infection models (cell lines and primary hepatocytes)